Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Mizuho Securities Stick to Their Hold Rating for SAGE Therapeutics

Published 10/10/2021, 06:15 PM
Updated 10/10/2021, 06:15 PM


Mizuho Securities analyst Vamil Divan maintained a Hold rating on SAGE Therapeutics (NASDAQ:SAGE) on Sunday, setting a price target of $52, which is approximately 15.45% above the present share price of $45.04.

Divan expects SAGE Therapeutics to post earnings per share (EPS) of -$1.83 for the fourth quarter of 2021.

The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in SAGE Therapeutics, with an average price target of $72.45.
The analysts price targets range from a high of $100 to a low of $50.

In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $1.64 million and a net profit of -$108.02 million. The company's market cap is $2.65 billion.

According to TipRanks.com, Mizuho Securities analyst Vamil Divan is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.5% and a 48.30% success rate.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.